Immunex Corp. said at the 20th annual World Congress of Dermatology Meeting in Paris that it began a second Phase III trial of Enbrel in psoriasis as the company seeks its fifth approval for the drug. (BioWorld Today)

Immunex Corp. said at the 20th annual World Congress of Dermatology Meeting in Paris that it began a second Phase III trial of Enbrel in psoriasis as the company seeks its fifth approval for the drug. (BioWorld Today)

ARYx Therapeutics Inc. raised $25 million in a Series C round of financing - it's largest to date - and will use the funds to continue its progress as the Volvo of the drug industry. (BioWorld Today)

ARYx Therapeutics Inc. raised $25 million in a Series C round of financing - it's largest to date - and will use the funds to continue its progress as the Volvo of the drug industry. (BioWorld Today)